Tests:Estradiol, Serum: Difference between revisions
- Department
- Biochemistry
Tests:Estradiol, Serum
No edit summary |
No edit summary |
||
| (5 intermediate revisions by 4 users not shown) | |||
| Line 5: | Line 5: | ||
{| class="wikitable" | {| class="wikitable" | ||
! colspan="2" | | ! colspan="2" | | ||
== | == Overview == | ||
|- | |- | ||
|Department | |Department | ||
| Line 21: | Line 21: | ||
17 beta estradiol | 17 beta estradiol | ||
|- | |||
|Availability | |||
|Monday to Friday | |||
Weekend and public holiday testing by arrangment | |||
|- | |- | ||
|Turnaround Time | |Turnaround Time | ||
| Line 26: | Line 30: | ||
|- | |- | ||
|Stability – Add test | |Stability – Add test | ||
| | |24 hours unseperated | ||
|- | |- | ||
! colspan="2" | | ! colspan="2" | | ||
== | == Specimen Requirements == | ||
|- | |- | ||
|Specimen | |Specimen | ||
|Serum | |Serum | ||
|- | |- | ||
| | |Preferred | ||
|<span style="background: #fbec5d">Yellow-Top</span> or <span style="background:#e30022"> Red-Top</span> tube | |||
|- | |||
|Acceptable | |||
| | | | ||
|- | |- | ||
| | |Unacceptable | ||
| | | | ||
|- | |- | ||
| | |Specimen Transportation | ||
| | | | ||
|- | |- | ||
| | |Paediatric Requirements | ||
|0.5 mL in a <span style="background:#e30022"> Red-Top</span> | |0.5 mL in a <span style="background:#e30022"> Red-Top</span> microtainer | ||
|- | |- | ||
! colspan="2" | | ! colspan="2" | | ||
== | == Aliquot Requirements == | ||
|- | |- | ||
|Sample | |Sample | ||
|Serum | |Serum | ||
|- | |||
|Preferred Volume | |||
| | |||
|- | |- | ||
|Minimum Volume | |Minimum Volume | ||
| Line 61: | Line 69: | ||
|- | |- | ||
! colspan="2" | | ! colspan="2" | | ||
== | == Clinical Information == | ||
|- | |- | ||
|Reference Intervals | |Reference Intervals | ||
| | | | ||
{| class="wikitable" | {| class="wikitable" | ||
| | |Units | ||
|pmol/L | |pmol/L | ||
|- | |||
| colspan="2" |Female : | |||
|- | |- | ||
|Follicular phase | |Follicular phase | ||
| Line 81: | Line 91: | ||
|<103 | |<103 | ||
|- | |- | ||
|Male | | colspan="2" | | ||
|- | |||
|Male : | |||
|<160 | |<160 | ||
|} | |} | ||
|- | |- | ||
|Test Method | |Test Method | ||
|Abbott Alinity | |Abbott Alinity i series analyser using Abbott reagents. Chemiluminescent microparticle immunoassay. | ||
|- | |- | ||
|Advanced Notice | |Advanced Notice | ||
| Line 98: | Line 108: | ||
|- | |- | ||
! colspan="2" | | ! colspan="2" | | ||
== | == Comments == | ||
|- | |- | ||
| colspan="2" |Samples from patients receiving oestrogen replacement | | colspan="2" |Samples from patients receiving oestrogen replacement therapy including Premarin may yield spurious oestradiol results. | ||
|} | |} | ||
{{DocMeta | |||
| owner = Crossley1 | |||
| review_ping = | |||
}} | |||
Latest revision as of 21:40, 23 September 2026
Overview | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Department | Biochemistry | ||||||||||||||||
| Test Code | TOES | ||||||||||||||||
| Synonyms | Oestradiol
Estradiol E2 17 beta estradiol | ||||||||||||||||
| Availability | Monday to Friday
Weekend and public holiday testing by arrangment | ||||||||||||||||
| Turnaround Time | 2 hrs – 2 days | ||||||||||||||||
| Stability – Add test | 24 hours unseperated | ||||||||||||||||
Specimen Requirements | |||||||||||||||||
| Specimen | Serum | ||||||||||||||||
| Preferred | Yellow-Top or Red-Top tube | ||||||||||||||||
| Acceptable | |||||||||||||||||
| Unacceptable | |||||||||||||||||
| Specimen Transportation | |||||||||||||||||
| Paediatric Requirements | 0.5 mL in a Red-Top microtainer | ||||||||||||||||
Aliquot Requirements | |||||||||||||||||
| Sample | Serum | ||||||||||||||||
| Preferred Volume | |||||||||||||||||
| Minimum Volume | 200ul | ||||||||||||||||
| Aliquot Transportation | |||||||||||||||||
Clinical Information | |||||||||||||||||
| Reference Intervals |
| ||||||||||||||||
| Test Method | Abbott Alinity i series analyser using Abbott reagents. Chemiluminescent microparticle immunoassay. | ||||||||||||||||
| Advanced Notice | |||||||||||||||||
| Patient Preparation | |||||||||||||||||
Comments | |||||||||||||||||
| Samples from patients receiving oestrogen replacement therapy including Premarin may yield spurious oestradiol results.
| |||||||||||||||||
| Owner | Clair Crossley (Crossley1) |
|---|---|
| Last reviewed | 23 Sep 2026 |
| Next review | 23 Sep 2027 OK |